Mankind Pharma IPO Details ( Mankind Pharma Limited IPO Review )
(25 Apr 2023 – 27 Apr 2023)
Mankind Pharma Limited, established in 1991, is a company that focuses on the development, production, and distribution of pharmaceutical formulations catering to a range of acute and chronic therapeutic areas, along with numerous consumer healthcare products.
Mankind Pharma Limited is actively involved in multiple acute and chronic therapeutic areas in India, including but not limited to anti-infectives, cardiovascular diseases, gastrointestinal issues, anti-diabetic treatments, neuro/CNS disorders, vitamins/minerals/nutrients deficiencies, and respiratory ailments.
With a vast range of products, Mankind Pharma Limited boasts over 36 brands, which include Manforce (Rx), Moxikind-CV, Amlokind-AT, Unwanted-Kit, Candiforce, Gudcef, Glimestar-M, Prega News, Dydroboon, Codistar, Nurokind-Gold, Nurokind Plus-RF, Nurokind-LC, Asthakind-DX, Cefakind, Monticope, Telmikind-H, Telmikind, Gudcef-CV, and Unwanted-72, among others.
Mankind Pharma boasts one of the largest distribution networks of medical representatives in the Indian pharmaceutical market (“IPM”). Over 80% of doctors in India prescribe their formulations, and the company was ranked fourth in terms of domestic sales during the Financial Year 2022.
Mankind Pharma has received numerous accolades, including The Best of Bharat Awards 2022 from exchange4media, the Silver Medal from National Awards for Manufacturing Competitiveness Assessment 2021 by the International Research Institute for Manufacturing, and the Silver Award for Good Health Brand at IHW Awards 2021. The company has also been recognized with the Best Condom Brand of the Year award at Sex Brand Awards, Pharma OTC Company of the Year Award at Pharma Excellence Awards 2018, Award for Best Design in Healthcare at Healthcare Leadership Awards 2017, and Amity HR Excellence Award for Performance Management at the 8th Global HR Summit 2011.
We operate 23 manufacturing facilities across India, in the states of Himachal Pradesh, Sikkim, Rajasthan, Andhra Pradesh and Uttarakhand, and had 2,181 manufacturing personnel as of March 31, 2022. Our formulation manufacturing facilities have a total installed capacity of 40.77 billion units across a wide range of dosage forms, including tablets, capsules, syrups, vials, ampoules, blow fill seal, soft and hard gels, eye drops, creams, contraceptives and other over-the-counter products, as of March 31, 2022.
Mankind Pharma Limited Our Products & Brands
- Manforce (Rx)
- Moxikind-CV
- Amlokind-AT
- Unwanted-Kit
- Candiforce
- Gudcef
- Glimestar-M
- Prega News
- Dydroboon
- Codistar
- Nurokind-Gold
- Nurokind Plus-RF
- Nurokind-LC
- Asthakind-DX
- Cefakind
- Monticope
- Telmikind-H
- Telmikind
- Gudcef-CV
- Unwanted-72
- Gas-O-Fast
Mankind Pharma Limited IPO Competitive Strength
- Scaled domestic focused business with potential for further growth
- Growing faster than the rate of the IPM with a focus on volume-led growth
- Diversified portfolio with market leading rankings across key therapeutic areas
- Established and growing consumer healthcare franchise with brand recall
- Leveraged our corporate brand to build and scale brands
- Wide market and distribution coverage with focus on affordability and accessibility
- Significant and diversified manufacturing and R&D capabilities
- Experienced and professional management team backed by private equity investors
Mankind Pharma IPO Financials Performance ( Results )
Mankind Pharma Limited Financial Information ( Restated Consolidated )
All Amount in ₹ Crore
| Period Ended | Total Assets | Total Revenue | PAT | EPS (₹) | Net Worth | NAV (₹) | Reserves | Borrowing |
| 31-Mar-20 | 5,073.29 | 5,975.65 | 1,056.15 | 25.72 | 3,485.31 | 87.00 | 3,436.34 | 126.92 |
| 31-Mar-21 | 6,372.63 | 6,385.38 | 1,293.03 | 31.59 | 4,722.00 | 117.88 | 4,674.39 | 234.53 |
| 31-Dec-21 | 8,043.88 | 6,218.29 | 1,260.24 | 31.04 | 5,965.46 | 148.92 | 0 | 268.70 |
| 31-Mar-22 | 9,147.74 | 7,977.58 | 1,452.96 | 35.78 | 6,155.23 | 153.65 | 6,106.06 | 868.03 |
| 31-Dec-22 | 9,273.75 | 6,777.82 | 1,015.98 | 24.87 | 7,145.89 | 178.38 | 0 | 167.93 |
Objective of IPO Issue
All of the offer proceeds will be received by the selling shareholders in proportion to the offered shares that each selling shareholder sold as part of the offer; the company will not receive any of the offer proceeds.
Mankind Pharma IPO Basic Details
| IPO Date | Apr 25, 2023 to Apr 27, 2023 |
| Listing Date | Monday, May 09, 2023 |
| Face Value | ₹1 per share |
| Price | ₹1026 to ₹1080 per share |
| Lot Size | 13 Shares |
| Issue Size | 40,058,844 shares (aggregating up to ₹4,326.36 Cr) |
| Offer for Sale | 40,058,844 shares (aggregating up to ₹4,326.36 Cr) |
| Issue Type | Book Built Issue IPO |
| Listing At | NSE, BSE |
| QIB Shares Offered | 50% of the Offer |
| NII (HNI) Shares Offered | 15% of the Offer |
| Retail Shares Offered | 35% of the Offer |
| Company Promoters | Ramesh Juneja, Rajeev Juneja, Sheetal Arora, Ramesh Juneja Family Trust, Rajeev Juneja Family Trust And Prem Sheetal Family Trust |
Mankind Pharma IPO Timetable
Mankind Pharma IPO will open on Apr 25, 2023 and close on Apr 27, 2023. You can join Mankind Pharma IPO at 10.00 A.M. to 5.00 p.m. Upto which mandate can be applied.
| Event | Date |
| Opening Date | Apr 25, 2023 |
| Closing Date | Apr 27, 2023 |
| Basis of Allotment | May 03, 2023 |
| Initiation of Refunds | May 04, 2023 |
| Credit of Shares to Demat | May 05, 2023 |
| Listing Date | May 09, 2023 |
Mankind Pharma IPO Lot Size
For retail investors in Mankind Pharma IPO, 13 shares will come in 1 lot or the minimum investment will be ₹14,040. Retail-individual investors can apply for up to 13 lots or the maximum investment will be ₹196,560.
| Application | Lots | Shares | Amount |
| Retail (Min) | 1 | 13 | ₹14,040 |
| Retail (Max) | 14 | 182 | ₹196,560 |
| S-HNI (Min) | 15 | 195 | ₹210,600 |
| S-HNI (Max) | 71 | 923 | ₹996,840 |
| B-HNI (Min) | 72 | 936 | ₹1,010,880 |
Mankind Pharma IPO Promoter Holding
| Pre Issue Share Holding | 79.00% |
| Post Issue Share Holding | 76.50% |
Mankind Pharma IPO Valuation – FY2022
| Earning Per Share (EPS) | ₹35.78 per Equity Share |
| Price/Earning P/E Ratio | 32.13 |
| Return on Net Worth (RoNW) | 23.29% |
| Net Asset Value (NAV) | ₹153.65 per Equity Share |
| Upper Price/Book Value (Price/BV) Ratio | Coming Soon |
Mankind Pharma Ltd Key Performance Indicator
| KPI | Values |
| Market Cap (₹ Cr.) | 43263.55 |
| P/E (x) | 32.13 |
| ROE (%) | 25.99% |
| ROCE (%) | 25.50% |
| EBITDA Margin (%) | 25.75% |
| Debt/Equity | 0.02 |
Mankind Pharma Ltd Peer Comparison
| Company Name | Consolidated/ Standalone | Face Value | EPS (₹) | P/E Ratio | RoNW (%) | NAV (₹) | P/BV Ratio |
| Mankind Pharma Limited | Consolidated | 1.00 | 35.78 | 32.13 | 23.29 | 153.65 | – |
| Listed Peers | |||||||
| Sun Pharmaceuticals Industries Limited | Consolidated | 1.00 | 13.60 | 65.38 | 6.82 | 200.10 | 4.54 |
| Cipla Limited | Consolidated | 2.00 | 31.20 | 33.85 | 12.08 | 258.32 | 3.41 |
| Zydus Lifesciences Limited | Consolidated | 1.00 | 43.83 | 8.54 | 26.40 | 166.05 | 3.13 |
| Torrent Pharmaceutical Limited | Consolidated | 5.00 | 22.97 | 66.02 | 13.06 | 175.89 | 8.85 |
| Alkem Laboratories | Consolidated | 2.00 | 137.63 | 23.14 | 19.05 | 722.44 | 4.40 |
| JB Chemicals & Pharmaceuticals Limited | Consolidated | 2.00 | 49.86 | 37.54 | 18.06 | 240.83 | 7.09 |
| Eris Lifesciences Limited | Consolidated | 1.00 | 29.89 | 23.43 | 21.28 | 140.39 | 4.12 |
| Ipca Laboratories Limited | Consolidated | 2.00 | 34.85 | 24.99 | 16.10 | 216.47 | 3.64 |
| Abbott India Limited | Consolidated | 10.00 | 375.86 | 48.46 | 28.32 | 1,327.00 | 17.7 |
| Glaxosmithkline Pharmaceuticals Limited | Consolidated | 10.00 | 100.04 | 14.27 | 63.64 | 157.19 | 14.4 |
| Dabur India Limited | Consolidated | 1.00 | 9.84 | 58.48 | 20.75 | 47.41 | 10.5 |
| Procter & Gamble Health Limited | Consolidated | 10.00 | 116.00 | 37.01 | 31.23 | 371.39 | 10.8 |
| Zydus Wellness Limited | Consolidated | 10.00 | 48.54 | 34.05 | 6.38 | 761.26 | 1.96 |
Mankind Pharma IPO GMP Live Update, Kostak Rate day by day
| Date | GMP | Kostak | Subject to |
| 9 May 2023 | ₹140 | – | – |
| 8 May 2023 | ₹135 | – | – |
| 7 May 2023 | ₹120 | – | – |
| 6 May 2023 | ₹102 | – | – |
| 5 May 2023 | ₹94 | – | – |
| 4 May 2023 | ₹86 | – | – |
| 3 May 2023 | ₹84 | – | – |
| 2 May 2023 | ₹82 | – | – |
| 1 May 2023 | ₹74 | – | – |
| 30 April 2023 | ₹34 | – | – |
| 29 April 2023 | ₹33 | – | – |
| 28 April 2023 | ₹32 | – | – |
| 27 April 2023 | ₹32 | – | – |
| 26 April 2023 | ₹28 | – | – |
| 25 April 2023 | ₹96 | – | – |
| 24 April 2023 | ₹90 | – | – |
| 23 April 2023 | ₹82 | – | – |
| 22 April 2023 | ₹82 | – | – |
| 21 April 2023 | ₹82 | – | – |
| 20 April 2023 | ₹85 | – | – |
| 19 April 2023 | ₹100 | – | – |
| 18 April 2023 | ₹75 | – | – |
Mankind Pharma IPO Detail Video:
Mankind Pharma IPO Subscription Status (Bidding Detail)
The Mankind Pharma IPO on Apr 27, 2023 at 7:02:00 PM was subscribed 15.32 times, with the retail category being subscribed 0.92 times, the NII (Non-Institutional Investor) category being subscribed 3.80 times and the QIB (Qualified-Institutional Buyers) category being subscribed 49.16 times.
| Category | Subscription |
| QIB | 49.16x |
| NII | 3.80x |
| Retail | 0.92x |
| Total | 15.32x |
Mankind Pharma IPO Prospectus
| Mankind Pharma IPO DRHP | Download |
| Mankind Pharma IPO RHP | Download |
Mankind Pharma IPO Rating
| Our Rating | 3.0/5.0 |
Mankind Pharma Company Contact Information
Mankind Pharma Limited
Registered Office: 208, Okhla Industrial Estate, Phase-III,
New Delhi 110 020, Delhi, India
Tel: +91 11 4747 6600
Corporate Office: 262, Okhla Industrial Estate, Phase-III,
New Delhi 110 020, Delhi, India
Tel: +91 11 4684 6700
Contact Person: Pradeep Chugh, Company Secretary and Compliance Officer
Tel: +91 11 4684 6729
E-mail: investors@mankindpharma.com
Website: www.mankindpharma.com
Corporate Identity Number: U74899DL1991PLC044843
Promoter Holding: Ramesh Juneja, Rajeev Juneja, Sheetal Arora, Ramesh Juneja Family Trust,
Rajeev Juneja Family Trust And Prem Sheetal Family Trust
Mankind Pharma IPO Registrar
KFin Technologies Limited
Registered Office: Selenium, Tower B, Plot No. 31 and 32 Financial District,
Nanakramguda, Serilingampally, Hyderabad, Rangareddi 500 032,
Telangana, India
Tel: +91 40 6716 2222
E-mail: mankind.ipo@kfintech.com
Website: www.kfintech.com
Investor Grievance E-mail: einward.ris@kfintech.com
Contact Person: M Murali Krishna
SEBI Registration No: INR000000221
Mankind Pharma IPO Lead Manager
Kotak Mahindra Capital Company Limited
Registered Office: 1st Floor, 27 BKC
Plot No. 27, ‘G’ Block, Bandra Kurla Complex , Bandra (East)
Mumbai 400 051, Maharashtra, India
Tel: +91 22 4336 0000
E-mail: mankindpharma.ipo@kotak.com
Investor Grievance E-mail: kmccredressal@kotak.com
Website: www.investmentbank.kotak.com
Contact Person: Ganesh Rane
SEBI Registration No.: INM000008704
Axis Capital Limited
Registered Office: 1st Floor, Axis House, C-2, Wadia International Centre
P.B. Marg , Worli Mumbai 400 025, Maharashtra, India
Tel: + 91 22 4325 2183
E-mail: mankindpharma.ipo@axiscap.in
Investor Grievance E-mail: complaints@axiscap.in
Website: www.axiscapital.co.in
Contact Person: Jigar Jain/Akash Aggarwal
SEBI Registration No.: INM000012029
IIFL Securities Limited
Registered Office: 10th Floor, IIFL Centre
Kamala City, Senapati Bapat Marg, Lower Parel (West)
Mumbai 400 013, Maharashtra, India
Tel: +91 22 4646 4728
E-mail: mankind.ipo@iiflcap.com
Investor Grievance E-mail: ig.ib@iiflcap.com
Website: www.iiflcap.com
Contact Person: Pinkesh Soni/Pawan Kumar Jain
SEBI Registration Number: INM000010940
Jefferies India Private Limited
Registered Office: 42/43, 2 North Avenue, Maker Maxity
Bandra-Kurla Complex (BKC), Bandra (East)
Mumbai 400 051, Maharashtra, India
Tel: +91 22 4356 6000
E-mail: Mankindpharma.ipo@jefferies.com
Investor Grievance E-mail: jipl.grievance@jefferies.com
Website: www. Jefferies.com
Contact Person: Suhani Bhareja
SEBI Registration No.: INM000011443
J.P. Morgan India Private Limited
Registered Office: J.P. Morgan Tower, Off CST Road, Kalina
Santacruz East Mumbai 400098, Maharashtra, India
Tel: +91 22 6157 3000
E-mail: mankind_IPO@jpmorgan.com
Investor Grievance E-mail: investor.smb.jpmipl@jpmorgan.com
Website: www.jpmorgan.com
Contact Person: Nidhi Wangnoo/Krishna Gohil
SEBI Registration No.: INM000002970
Mankind Pharma IPO FAQs
What is the lot size of Mankind Pharma IPO?
The total size of Mankind Pharma IPO is ₹4,326.36 crores and this is a complete offer for sale (OFS) Issue.
When will Mankind Pharma IPO start?
Mankind Pharma IPO will Open from 25 April 2023 and IPO will Close on 27 April 2023.
What is the open date of Mankind Pharma IPO?
Mankind Pharma IPO will open date from 25 April 2023.
What is the last date ( close date ) of Mankind Pharma IPO?
Mankind Pharma IPO will close from 27 April 2023.
What is the price band of Mankind Pharma IPO?
Mankind Pharma IPO price band is ₹1026 to ₹1080. ( Upper Price Band: ₹1080, Lower Price Band: ₹1026 )
What is the minimum amount required to apply for Mankind Pharma IPO?
The minimum investment for retailers to apply for Mankind Pharma IPO is ₹14,040 and the maximum investment is ₹196,560.
What is going on gray market premium of Mankind Pharma IPO?
View gray market premium of Mankind Pharma IPO by Clicking Here
How much is the GMP of Mankind Pharma IPO?
Watch Mankind Pharma IPO GMP Today: Click Here
What is the allotment date of Mankind Pharma IPO?
The allotment date of Mankind Pharma IPO is 03 May 2023.
How to check allotment status in Mankind Pharma IPO?
To check the allotment status of Mankind Pharma IPO, first of all go to the registrar website by clicking here, select your bad Mankind Pharma IPO name or enter your bad application number, PAN number or client ID and click on submit. ( Video Link )
What is the listing date of Mankind Pharma IPO?
The Listing Date of Mankind Pharma IPO is 09 May 2023.
How much will be the listing gain in Mankind Pharma IPO?
View listing gain of Mankind Pharma IPO by Clicking Here
How much time Mankind Pharma IPO is subscribed?
Total 15.32 times subscribed in Mankind Pharma IPO out of which 0.92 times subscription was done in retail quota, 3.80 times subscription in NII quota and 49.16 times subscription in QIB quota.
How to apply for Mankind Pharma IPO from Upstox?
Click Here to see how to apply for Mankind Pharma IPO from Upstox. (step by step)
How to apply for Mankind Pharma IPO from Zerodha?
Click Here to see how to apply for Mankind Pharma IPO from Zerodha. (step by step)
How to apply for Mankind Pharma IPO from Angle One?
Click Here to see how to apply for Mankind Pharma IPO from Angle One. (step by step)
